Ethyreal lands $101M Series A to treat Graves' and thyroid eye disease

What's the deal? Ethyreal, a new biotech startup, has emerged from stealth with $101M in Series A funding to develop treatments for two related autoimmune conditions: Graves' disease and thyroid eye disease. The round was led by Atlas Venture and MedicxiDealroom has a profile for this one. Try Dealroom →.

Why now? Graves' disease and thyroid eye disease are closely linked — the latter often develops as a consequence of the former — yet current treatments typically address them separately. Ethyreal appears to be betting that a unified therapeutic approach could serve patients better.

The signal: A $101M Series A is a hefty debut, reflecting continued investor appetite for autoimmune and rare disease biotechs with clearly defined targets. Atlas Venture and Medicxi are established life sciences investors, and their backing suggests confidence in the science behind Ethyreal's approach. The deal adds to a broader trend of well-capitalised biotech launches tackling conditions where existing therapies leave significant gaps.

Read more: endpoints.news